Published in:
01-09-2019 | Computed Tomography | Oncology
Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling
Published in: European Radiology | Issue 9/2019
Login to get accessAbstract
Objectives
The tyrosine kinase inhibitor (TKI)-sensitive mutations of the epidermal growth factor receptor (EGFR) gene is essential in the treatment of lung adenocarcinoma. To overcome the difficulty of EGFR gene test in situations where surgery and biopsy samples are too risky to obtain, we tried a noninvasive imaging method using radiomics features and random forest models.
Methods
Five hundred three lung adenocarcinoma patients who received surgery-based treatment were included in this study. The diagnosis and EGFR gene test were based on resections. TKI-sensitive mutations were found in 60.8% of the patients. CT scans before any invasive operation were gathered and analyzed to extract quantitative radiomics features and build random forest classifiers to identify EGFR mutants from wild types. Clinical features (sex and smoking history) were added to the image-based model. The model was trained on a set of 345 patients and validated on an independent test group (n = 158) using the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity.
Results
The performance of the random forest model with 94 radiomics features reached an AUC of 0.802. Its AUC was further improved to 0.828 by adding sex and smoking history. The sensitivity and specificity are 60.6% and 85.1% at the best diagnostic decision point.
Conclusion
Our results showed that radiomics could not only reflect the genetic differences among tumors but also have diagnostic value and the potential to be a diagnostic tool.
Key Points
• Radiomics provides a potential noninvasive method for the prediction of EGFR mutation status.
• In situations where surgeries and biopsy are not available, CT image-based radiomics models could help to make treatment decisions.
• The accuracy, sensitivity, and specificity still need to be improved before the image-based EGFR identifier could be used in clinics.